Buchumschlag

An Empirical Assessment of the Cost of Dichotomization of the Outcome of Clinical Trials

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Erik W. van Zwet, Frank E. Harrell, Stephen J. Senn
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	Statistics in Medicine
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Instability of the AUROC of Clinical Prediction Models
von: Florian D. van Leeuwen, et al.
Veröffentlicht: (2025)

Longitudinal Extension of the Win Odds for Ordinal Repeated Measurements
von: Yongxi Long, et al.
Veröffentlicht: (2026)

Testing for Similarity of Dose Response in Multiregional Clinical Trials
von: Holger Dette, et al.
Veröffentlicht: (2025)

Variability in Causal Effects and Noncompliance in a Multisite Trial: A Bivariate Hierarchical Generalized Random Coefficients Model for a Binary Outcome
von: Xinxin Sun, et al.
Veröffentlicht: (2024)

Doubly Robust Estimation and Sensitivity Analysis With Outcomes Truncated by Death in Multi‐Arm Clinical Trials
von: Jiaqi Tong, et al.
Veröffentlicht: (2025)

Futility Monitoring in Clinical Trials
von: Ana M. Ortega‐Villa, et al.
Veröffentlicht: (2025)

Accounting for Carryover Toxicity in Phase I Clinical Trials with Intra‐Patient Dose Escalation
von: Chloe E. Falke, et al.
Veröffentlicht: (2025)

Patient‐Centric Pragmatic Clinical Trials: Opening the DOOR
von: Scott R. Evans, et al.
Veröffentlicht: (2026)

RMST for Interval‐Censored Data in Oncology Clinical Trials
von: Xiyuan Gao, et al.
Veröffentlicht: (2025)

Dynamic Borrowing From Historical Controls via the Synthetic Prior With Covariates in Randomized Clinical Trials
von: Daniel E. Schwartz, et al.
Veröffentlicht: (2026)

Clinical Trial Simulation: Planning With the OCTAVE Framework, Implementation and Validation Principles
von: Kim May Lee, et al.
Veröffentlicht: (2026)

Bayesian Ordered Lattice Design for Phase I Clinical Trials
von: Gi‐Ming Wang, et al.
Veröffentlicht: (2026)

Preference‐Informed Cluster Randomized Design for Pragmatic Clinical Trials
von: Yuwei Cheng, et al.
Veröffentlicht: (2026)

Adaptive Biomarker‐Based Design for Early Phase Clinical Trials
von: Alessandra Serra, et al.
Veröffentlicht: (2025)

Response‐Adaptive Randomization Procedure in Clinical Trials with Surrogate Endpoints
von: Jingya Gao, et al.
Veröffentlicht: (2024)

Designing Stepped Wedge Cluster Randomized Trials With a Baseline Measurement of the Outcome
von: Kendra Davis‐Plourde, et al.
Veröffentlicht: (2025)

A Biomarker Signature‐Guided Clinical Trial Design for Precision Medicine
von: Yuan Li, et al.
Veröffentlicht: (2025)

On Inclusion of Covariates in Model Based Dose Finding Clinical Trial Designs
von: Adrien Ollier, et al.
Veröffentlicht: (2025)

Empirical Sandwich Variance Estimator for Iterated Conditional Expectation g‐Computation
von: Paul N. Zivich, et al.
Veröffentlicht: (2024)

A Saddlepoint Framework for Accurate Inference in Multicenter Clinical Trials With Imbalanced Clusters
von: Haidy A. Newer
Veröffentlicht: (2026)

Sequential Monitoring of Covariate‐Adaptive Randomized Clinical Trials With Non‐Parametric Approaches
von: Xiaotian Chen, et al.
Veröffentlicht: (2025)

Handling Missing Outcome Data in Cluster Randomized Trials With Both Individual‐ and Cluster‐Level Dropout
von: Analissa Avila, et al.
Veröffentlicht: (2025)

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
von: Moka Komaki, et al.
Veröffentlicht: (2026)

Bayesian Power Prior in Platform Trials With Non‐Concurrent Control for Binary Outcomes: Development and Comparative Evaluation
von: Junichi Asano, et al.
Veröffentlicht: (2026)

A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes
von: Yichen Yan, et al.
Veröffentlicht: (2025)

Synergy Area With FDR ‐Controlled Evaluation ( SAFE ) to Robustly Assess Safety Profile in Clinical Trials
von: Tianyu Zhan, et al.
Veröffentlicht: (2026)

Matching‐Assisted Power Prior for Incorporating Real‐World Data in Randomized Clinical Trial Analysis
von: Ruoyuan Qian, et al.
Veröffentlicht: (2025)

The Cox Model With Adaptive Fused Group Bridge Penalty to Incorporate Historical Data Into the Analysis of Clinical Trials With an Application to BMT CTN 1101
von: Xi Fang, et al.
Veröffentlicht: (2025)

Unlocking Cognitive Analysis Potential in Alzheimer's Disease Clinical Trials: Investigating Hierarchical Linear Models for Analyzing Novel Measurement Burst Design Data
von: Guoqiao Wang, et al.
Veröffentlicht: (2024)

A Latent‐factor MCACE Model for Multidimensional Outcomes and Treatment Noncompliance with Application to a Longitudinal Trial of Arthritis Health Journal
von: Lulu Guo, et al.
Veröffentlicht: (2026)

Exact Randomized Two‐Stage Phase 2 Clinical Trial Designs for Two Binary Co‐Primary Endpoints
von: Hyejung Jung, et al.
Veröffentlicht: (2026)

Negative Control Outcome Adjustment in Early‐Phase Randomized Trials: Estimating Vaccine Effects on Immune Responses in HIV Exposed Uninfected Infants
von: Ethan Ashby, et al.
Veröffentlicht: (2025)

The Design of Large‐Scale Plasma Donation Trials
von: Kecheng Li, et al.
Veröffentlicht: (2025)

Identifying Less Burdensome and More Cost‐Efficient Incomplete Stepped Wedge Designs for Continuous Outcomes Collected via Repeated Cross‐Sections
von: Ehsan Rezaei‐Darzi, et al.
Veröffentlicht: (2025)

The Win Ratio Approach in Bayesian Monitoring for Two‐Arm Phase II Clinical Trial Designs With Multiple Time‐To‐Event Endpoints
von: Xinran Huang, et al.
Veröffentlicht: (2024)

Interconnections of Multimorbidity‐Related Clinical Outcomes: Analysis of Health Administrative Claims Data With a Dynamic Network Approach
von: Hao Mei, et al.
Veröffentlicht: (2025)

A two‐stage group‐sequential design for delayed treatment responses with the possibility of trial restart
von: Stephen Schüürhuis, et al.
Veröffentlicht: (2024)

Design and Analysis of N‐Of‐1 Trials That Incorporate Sequential Monitoring
von: Shu Jiang, et al.
Veröffentlicht: (2025)

Using Propensity Score Weighting With Clustered Data When the Treatment Is Applied at the Level of the Cluster and Outcomes Are Assessed at the Level of the Individual: The Observational Analog of Cluster Randomization Trials
von: Peter C. Austin
Veröffentlicht: (2026)

Active‐Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo
von: Fei Gao, et al.
Veröffentlicht: (2025)